Finance News World

Follicular Lymphoma Pipeline Insight

Follicular Lymphoma Pipeline constitutes 50+ key companies continuously working towards developing 55+ Follicular Lymphoma treatment therapies, analyzes DelveInsight.

Follicular Lymphoma Overview:

Follicular lymphoma (FL) is an indolent B-cell non-Hodgkin lymphoma (NHL), accounting for 20–30% of all NHL cases. While not typically curable, FL is often managed as a chronic condition, with patients living for many years post-diagnosis. FL originates from germinal center B-cells and is characterized by abnormal proliferation of malignant B-cells, leading to lymph node enlargement, spleen or bone marrow involvement, and potential spread to other tissues and organs.

The hallmark genetic mutation in FL is the translocation t(14;18)(q32;q21), causing overexpression of BCL2, an anti-apoptotic protein. About 5% of cases involve deregulated BCL6, critical for germinal center formation and transcription regulation. Other implicated genes include those related to cell cycle arrest, such as p21 and p16.

“Follicular Lymphoma Pipeline Insight 2025” report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Follicular Lymphoma Therapeutics Market.

Key Takeaways from the Follicular Lymphoma Pipeline Report

• DelveInsight’s Follicular Lymphoma pipeline report depicts a robust space with 50+ active players working to develop 55+ pipeline therapies for Follicular Lymphoma treatment.

• In August 2025, the company plans to submit a supplemental Biologics License Application (sBLA) for tafasitamab by the end of the year. This application targets the treatment of patients with follicular lymphoma (FL) who have not responded to at least one prior systemic anti-CD20 immunotherapy or chemo-immunotherapy, based on positive Phase III trial results.

• In June 2025, a consortium led by Eugene Private Equity and Korea Development Bank Private Equity announced the acquisition of an 80% stake in South Korean vaccine manufacturer Boryung Biopharma Co. for 320 billion won (approximately USD 231 million).

• In February 2025, Incyte revealed it had entered into an asset purchase agreement with MorphoSys AG, granting Incyte exclusive global rights to tafasitamab. Following this agreement, Incyte will assume full responsibility for U.S. commercialization and clinical development, with MorphoSys no longer eligible for milestone payments, profit shares, or royalty payments.

• Key Follicular Lymphoma companies such as Mab Works, AstraZeneca, ADC Therapeutics, Xynomic Pharmaceuticals, AbbVie, Nurix, InnoCare Pharma, LTZ Therapeutics, Hutchmed, Regeneron Pharmaceuticals, Pfizer, InnoCare Pharma, TriSalus Life Sciences, BeiGene, and others are evaluating new drugs for Follicular Lymphoma to improve the treatment landscape.

• Promising Follicular Lymphoma pipeline therapies in various stages of development include MIL62, AZD0486, Abexinostat, ABBV-319, NX-2127, and others.

Follicular Lymphoma Pipeline Analysis

The report provides insights into:

• The report provides detailed insights into the key companies that are developing therapies in the Follicular Lymphoma Market.

• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Follicular Lymphoma treatment.

• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Follicular Lymphoma market.

Download our free sample page report on Follicular Lymphoma pipeline insights

Follicular Lymphoma Emerging Drugs

• MIL62: MAB WORKS

• AZD0486: AstraZeneca

• Abexinostat: Xynomic Pharmaceuticals

• ABBV-319: AbbVie

• NX-2127: Nurix Therapeutics, Inc.

Follicular Lymphoma Companies

Over 50 prominent companies are actively working on developing therapies for Follicular Lymphoma. Among these, MAB WORKS and AstraZeneca have drug candidates in the most advanced stage of development, specifically Phase III trials.

DelveInsight’s report covers around 22+ products under different phases of clinical development like

• Late stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I) along with the details of

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

Follicular Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous

• Subcutaneous

• Oral

• Intramuscular

Follicular Lymphoma Products have been categorized under various Molecule types such as

• Monoclonal antibody

• Small molecule

• Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Follicular Lymphoma Therapies and Key Companies: Follicular Lymphoma Clinical Trials and advancements

Follicular Lymphoma Pipeline Therapeutic Assessment

• Follicular Lymphoma Assessment by Product Type

• Follicular Lymphoma By Stage

• Follicular Lymphoma Assessment by Route of Administration

• Follicular Lymphoma Assessment by Molecule Type

Download Follicular Lymphoma Sample report to know in detail about the Follicular Lymphoma treatment market @ Follicular Lymphoma Therapeutic Assessment

Table of Content

1. Report Introduction

2. Executive Summary

3. Follicular Lymphoma Current Treatment Patterns

4. Follicular Lymphoma – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Follicular Lymphoma Late-Stage Products (Phase-III)

7. Follicular Lymphoma Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Follicular Lymphoma Discontinued Products

13. Follicular Lymphoma Product Profiles

14. Follicular Lymphoma Key Companies

15. Follicular Lymphoma Key Products

16. Dormant and Discontinued Products

17. Follicular Lymphoma Unmet Needs

18. Follicular Lymphoma Future Perspectives

19. Follicular Lymphoma Analyst Review

20. Appendix

21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Follicular Lymphoma Pipeline Reports Offerings: https://www.delveinsight.com/report-store/follicular-lymphoma-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/